ANGO Earnings Prediction
The chart below shows how ANGO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ANGO sees a +2.30% change in stock price 10 days leading up to the earnings, and a -6.01% change 10 days following the report. On the earnings day itself, the stock moves by -0.42%. This data can give you a slight idea of what to expect for the next quarter's release.
ANGO Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
72.84M
-7.88%
7.93%
Gross Margin
51.27%
10.47%
1.30%
Operating Margin
-6.96%
-18.02%
-46.09%
Net Margin
-14.74%
-59.88%
-22.26%
EPS
-0.26
-63.89%
-16.13%
No Data Available
ANGO Earnings Analysis
AngioDynamics Inc Corporation (ANGO.O) Earnings Conference Call
Positive
Worldwide Revenue Growth: Total worldwide revenue was $73 million, representing growth of approximately 9% year-over-year.
MedTech Segment Growth: Our MedTech segment had yet another excellent quarter, growing 25%, led by growth across all of our platforms.
EBITDA and Cash Flow: We reported adjusted EBITDA of $3.1 million and generating $2.5 million in operating cash flow.
NanoKnife Revenue Increase: Total NanoKnife revenue was $6 million, an increase of 4.9% over the prior year quarter.
Revenue Increase 50.7%: AngioVac generated $8.1 million of revenue, an increase of 50.7% year-over-year.
Negative
Quarterly Revenue Increase: Total revenue for the second quarter of FY 2025 increased 9.2% year-over-year to $73 million, driven by growth in both our Med Tech and US med device platforms. However, the Med device revenue was flat compared to the second quarter of FY 2024, indicating stagnation in this segment.
Adjusted Net Loss Analysis: Adjusted net loss for the second quarter of FY 2025 was $1.7 million, or an adjusted loss per share of $0.04, compared to an adjusted net loss of $3.4 million, or an adjusted loss per share of $0.08, in the second quarter of last year, showing ongoing financial challenges despite improvements.
SG&A Expense Analysis: SG&A expense for the second quarter of FY 2025 was $36 million, representing 49.3% of sales, compared to $33.2 million, or 49.7% of sales, a year ago, indicating a high cost structure that is not improving significantly.
Gross Margin Decline: The gross margin for the second quarter of FY 2025 was 54.7%, a decrease of 10 basis points compared to the year-ago period, suggesting pressure on profitability despite revenue growth.
Adjusted EBITDA Performance: Adjusted EBITDA in the second quarter of FY 2025 was a gain of $3.1 million, compared to a loss of $10,000 in the second quarter of 2024, indicating volatility in operational performance despite some improvements.
ANGO FAQs
How does ANGO typically perform around its earnings report dates?
Is AngioDynamics, Inc. (ANGO) Q2 2025 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ANGO Earning Call Sentiment
AngioDynamics, Inc. (ANGO) Q2 2025 Earnings Call Transcript
1.0x
00:00
00:00
ANGO.O
-2.09%Positive
The earnings call summary reflects a positive outlook with projected revenue growth, improved adjusted earnings, and upward-trending gross margins for FY 2025. Financial performance shows strong year-over-year improvements in revenue, gross margin, operating income, and cash flow. Despite some regulatory and competitive risks, management's optimism and strategic focus on new product launches and supply chain improvements support a positive sentiment. The Q&A section, while lacking specific details, does not reveal significant negative sentiment from analysts. Overall, these factors suggest a likely positive stock price movement in the short term.